TCS to steady operational efficiency of Danish retailer, Salling Group
TCS has entered a long-term, strategic partnership with Danish retailer Salling Group to drive sustainability, technology innovations and improve organisational efficiency.
This collaboration would cover Salling Group's 2,100 stores, brands and 68,000 employees across Denmark, Poland, Germany, Estonia, Lithuania and Latvia including BR, a nationwide toy store chain, franchise quick-service restaurants Carl's Jr. and Starbucks, and grocers føtex, Bilka, Netto and RIMI Baltic.
As part of this partnership, TCS would help the Salling Group's cloud adoption journey and subsequently stabilise the operations to drive more agility, scalability, and sustainability. Additionally, TCS would support the retail group's digital transformation, focusing on enhancing the e-commerce platform to be more responsive to the evolving consumer demands.
TCS would also leverage its AI-enabled cloud operations solution, Cloud Exponence, which applies a Machine First approach and optimizes machine-human collaboration to deliver smart managed services in hybrid cloud environments. Through the power of AI and intelligent automation of operational tasks, along with built-in security and compliance, the solution reduces cloud management overheads, offers consistent service delivery experience and provides full-stack infrastructure services.
Vikram Sharma, Country Head, TCS Denmark, said, 'Salling Group is an esteemed and successful retail group with a century long legacy, playing a vital role in the Danish community and across Europe. We will bring our global retail experience and technical prowess to help the Salling Group build resilience and unlock new technologies to help drive their strategic goals.'
TCS has had a strong presence in Denmark for the past 30 years. Currently, over 20,000 TCS employees support leading enterprises in the Nordics, driving growth and transformation for some of the region's top multinationals in sectors such as banking, financial services, insurance, telecom, and hi-tech, said the tech firm.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
an hour ago
- Time of India
APSCHE charts tech future with quantum-AI curriculum
Visakhapatnam: In a bid to create the 'Amaravati Quantum Valley' and make the state a globally recognised hub for emerging technologies, the Andhra Pradesh State Council of Higher Education (APSCHE) is spearheading the development of a robust curriculum framework for quantum computing, quantum technologies, and artificial intelligence. Tired of too many ads? go ad free now APSCHE's vision aligns with the National Education Policy 2020 and AICTE guidelines. The APSCHE recently convened an expert committee meeting, chaired by its chairman, Prof K Madhu Murthy, to chart the path forward. The committee, constituted earlier for this purpose, comprises a diverse group of experts from govt, academia, and industry, ensuring a holistic approach to the development of a curriculum for quantum computing, quantum technologies, and AI. After thorough deliberations, the committee agreed to introduce three minor degree programmes: an 18-credit minor in quantum technologies for engineering students, a 16-credit minor in quantum technologies for general stream students, and an 18-credit minor in artificial intelligence open to both engineering and general streams. The curriculum prioritises practical learning and hands-on exposure, aiming to equip both engineering and non-engineering undergraduates with strong theoretical foundations and applied skills through laboratory work and projects. To support this initiative, faculty development programmes are planned for 500 faculty members across physics, computer science, electronics, and mathematics, with institutional support from the department of science and technology, TCS, and IBM. Training will be hosted at various IITs. Infrastructure support includes the proposed establishment of quantum laboratories at Andhra University, JNTU-Kakinada, Acharya Nagarjuna University, Sri Venkateswara University, JNTU-Anantapur, and RGUKT, with the possibility of extending support to autonomous colleges also under consideration. On the innovation front, APSCHE is collaborating with DST, TCS, IBM, and premier research institutions such as the IITs, IISERs, and IISc to promote research, start-ups, and a culture of innovation through boot camps and hackathons.
Time of India
5 hours ago
- Time of India
Hims stock tanks over 20% after Wegovy deal collapse — why Novo Nordisk's breakup over weight loss drugs is shaking up Wall Street
Hims stock plunges over 20% after Novo Nordisk ends Wegovy partnership: Hims & Hers Health Inc. (HIMS) took a hard hit in the stock market on Monday after Novo Nordisk called off its partnership with the company. The abrupt decision from Novo came amid growing concerns over the sale of compounded versions of semaglutide—better known by its brand name, Wegovy. Hims stock dropped more than 20% following the news, rattling investors and raising fresh questions about the future of weight-loss drug offerings on the platform. Why did Novo Nordisk end its deal with Hims & Hers? On June 23, 2025, Danish drugmaker Novo Nordisk officially announced that it had terminated its agreement with Hims & Hers. This partnership was just a couple of months old, announced in April, and was originally built around expanding access to weight-loss treatments like Wegovy, Novo's flagship semaglutide-based medication. But the deal unraveled quickly. According to reports from Barron's and CNBC, Novo Nordisk raised concerns that Hims was selling unapproved compounded versions of semaglutide, a practice that might violate U.S. drug safety regulations. Novo accused Hims of 'deceptive promotion' and highlighted the potential risks of offering these formulations, some of which could have come from questionable suppliers. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Elegant New Scooters For Seniors In 2024: The Prices May Surprise You Mobility Scooter | Search Ads Learn More Undo The FDA had recently taken semaglutide off its drug shortage list in April 2025, meaning that compounded versions of the drug were no longer allowed to be sold under most circumstances. That put Hims' weight-loss offerings in the spotlight—and clearly, Novo Nordisk didn't want to be associated with what could be seen as legally gray activity. How did this impact Hims stock and what numbers tell the story? The effect on Hims stock was immediate and severe. The stock price plummeted over 20% in early Monday trading. According to real-time trading data: Live Events HIMS opened at $62.69 It fell as low as $47.76 The price hovered around $64.22 later in the day, but volatility remained high Volume surged to over 16.8 million shares , much higher than average Market Cap dropped to around $6.56 billion At one point, the stock was down nearly 23% , erasing months of gains. This decline reflects not only the loss of a major partnership but also growing worries about regulatory compliance and reputational damage. By contrast, Novo Nordisk stock (NVO) dipped only slightly: NVO traded at $73.77 , down about 0.32% Intraday low reached $68.05 , but it recovered quickly Volume stood at just over 1.6 million shares So while Novo suffered a short-term dip, it's clear that Hims bore the brunt of the market reaction. Why did Novo Nordisk cut ties with Hims & Hers over Wegovy? Novo Nordisk said it made the decision after investigating Hims & Hers' practices related to compounded versions of Wegovy. While compounded medications are sometimes allowed during FDA-declared shortages or for specific medical needs, the company claims Hims & Hers crossed legal lines by promoting and selling these alternatives on a mass scale—even after Wegovy's supply stabilized in the U.S. In its official statement, Novo Nordisk said Hims & Hers had 'failed to adhere to the law which prohibits mass sales of compounded drugs' and accused the platform of 'deceptive' marketing that could endanger patient safety. The company clarified that it still supports the use of telehealth to increase access to Wegovy but will only work with providers who 'share our commitment to safe and effective medical treatment for patients living with chronic diseases.' What are compounded drugs and why are they controversial? Compounded drugs are custom-made medications prepared by pharmacists when a patient can't take a commercially available drug—for example, due to allergies or difficulty swallowing pills. However, these medications are not FDA-approved and can only be produced legally under strict circumstances. During shortages, like the one Wegovy faced last year, compounding became more common. But since Novo Nordisk has resolved the shortage in the U.S., the FDA rules now prohibit widespread compounding of the drug. Critics, including Novo Nordisk, argue that compounded versions can be risky because they may come from suppliers that don't meet FDA quality standards. The company cited an April report by the Brookings Institution which found many active ingredients used in knock-off Wegovy versions were sourced from Chinese manufacturers, most of which were never inspected by the FDA—or failed inspections due to quality violations. How did Hims & Hers respond to the Wegovy sales controversy? As of Monday morning, Hims & Hers had not issued a public response to the termination of the partnership. During a May earnings call, CEO Andrew Dudum defended the company's model by saying it gives both providers and patients autonomy in treatment decisions. 'Ultimately what is right for them is their own discretion,' Dudum said. 'We strongly believe it's really important that we maintain that independence.' Hims & Hers has marketed itself as a convenient, affordable alternative for those seeking wellness and prescription treatments online. But this controversy could call into question the regulatory oversight of such platforms, especially in the booming weight loss sector. What does this mean for consumers looking for Wegovy online? Patients interested in Wegovy should be cautious when purchasing medications online. Novo Nordisk's move to cut ties with Hims & Hers serves as a warning about the dangers of using unapproved, compounded weight loss drugs that may come from unverified international suppliers. The safest route, experts say, is to get FDA-approved Wegovy through verified telehealth providers or in-person doctors who comply with legal and medical standards. Novo Nordisk emphasized it will continue working with telehealth organizations that follow the law and prioritize patient safety. How is this affecting the telehealth and weight loss drug market? Shares of Hims & Hers dropped about 20% in early Monday trading, signaling investor concern over regulatory scrutiny and the company's future access to high-demand drugs like Wegovy. The split also raises broader questions about how telehealth companies operate in the fast-expanding weight loss drug space, which includes blockbuster drugs like Ozempic and Zepbound. The rivalry between branded pharmaceuticals and compounded alternatives has only intensified as more Americans seek prescription treatments for weight loss. With Novo Nordisk's decision, telehealth companies may now face increased pressure to ensure legal compliance and transparency in how they promote and distribute medications. FAQs: Q1: Why did Novo Nordisk end its deal with Hims & Hers over Wegovy? Novo Nordisk ended it due to illegal sales of unapproved compounded versions of Wegovy. Q2: Is it safe to buy Wegovy from telehealth platforms? Only FDA-approved Wegovy from trusted providers is considered safe.
Mint
5 hours ago
- Mint
Novo Nordisk exits obesity-drug partnership with Hims & Hers, cites compounding concerns
Danish drugmaker Novo Nordisk A/S said on Monday it is terminating a recently formed obesity-drug partnership with Hims & Hers Health Inc, citing concerns about sales of compounded drugs and misleading marketing. The partnership had been touted as a way to boost obesity-drug sales in the US. Shares of Hims & Hers plunged 18% in trading before US stock exchanges opened. Novo lost as much as 5% in Copenhagen.
